全文获取类型
收费全文 | 201篇 |
免费 | 43篇 |
专业分类
儿科学 | 4篇 |
基础医学 | 12篇 |
临床医学 | 5篇 |
内科学 | 21篇 |
皮肤病学 | 2篇 |
特种医学 | 4篇 |
外科学 | 119篇 |
综合类 | 10篇 |
预防医学 | 49篇 |
药学 | 17篇 |
中国医学 | 1篇 |
出版年
2023年 | 9篇 |
2022年 | 12篇 |
2021年 | 26篇 |
2020年 | 22篇 |
2019年 | 20篇 |
2018年 | 23篇 |
2017年 | 15篇 |
2016年 | 16篇 |
2015年 | 10篇 |
2014年 | 15篇 |
2013年 | 9篇 |
2012年 | 9篇 |
2011年 | 12篇 |
2010年 | 12篇 |
2009年 | 11篇 |
2008年 | 6篇 |
2007年 | 4篇 |
2006年 | 2篇 |
2005年 | 2篇 |
2004年 | 1篇 |
2003年 | 1篇 |
2000年 | 1篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1989年 | 2篇 |
1984年 | 1篇 |
排序方式: 共有244条查询结果,搜索用时 15 毫秒
81.
Christoph Troppmann Chandrasekar Santhanakrishnan Junichiro Sageshima John McVicar Richard Perez 《American journal of transplantation》2019,19(8):2168-2173
Live and deceased kidney donation by the numerous patients with advanced, progressive systemic neurological diseases, and other chronic neurological conditions (eg, high C‐spine injury) remains largely unexplored. In a review of our current clinical practice, we identified multiple regulatory and clinical barriers. For live donation, mandatory reporting of postdonation donor deaths within 2 years constitutes a strong programmatic disincentive. We propose that the United Network for Organ Sharing should provide explicit regulatory guidance and reassurance for programs wishing to offer live donation to patients at higher risk of death during the reporting period. Under the proposal, live donor deaths within 30 days would still be regarded as donation‐related, but later deaths would be related to the underlying disease. For deceased donation, donation after circulatory death (DCD) immediately following self‐directed withdrawal of life‐sustaining treatment (“conscious DCD”) is not universally covered by existing DCD agreements with donor hospitals. Organ procurement organizations should thus systematically strive to revise these agreements. Obtaining adequate first‐person consent from these communicatively severely impaired patients may be challenging. Optimized preservation and allocation protocols may maximize utilization of these DCD kidneys. Robust public debate and action by all stakeholders is necessary to lower existing barriers and maximize donation opportunities for patients with chronic neurological conditions. 相似文献
82.
83.
84.
据统计二级医院在国家注册的医院中占到总数的35%左右,一级(含以下)占到59%左右,三级医院占到6%左右。现代医院的发展和竞争逐步集中在人才和设备两个方面,设备科作为医院医疗设备管理的主要科室,肩负着重要的保障作用。科室的科学化管理将为临床一线提供强有力的保障。现根据我院设备科科室分工中存在的问题,有针对性地提出了自己的建议。 相似文献
85.
Samantha M. Noreen David Klassen Roger Brown Yolanda Becker Kevin O'Connor Jennifer Prinz Matthew Cooper 《American journal of transplantation》2022,22(1):210-221
Opportunities continue to be lost with a high rate of kidneys recovered for transplant but not utilized, particularly those considered less than ideal quality. The Organ Procurement and Transplantation Network (OPTN) Organ Center is tasked with allocating arguably the most difficult-to-place kidneys, and we hypothesized an accelerated placement pathway would increase utilization of kidneys placed by the Organ Center. The Kidney Accelerated Placement (KAP) project, implemented by the Organ Center from July 18, 2019 to July 15, 2020, aimed to offer kidneys with a high kidney donor profile index to programs that had a history of accepting such organs. We compared OPTN kidney match run, donor, and transplant recipient data during the project period and 1 year prior. There was no statistically significant change in the percentage of KAP-eligible donors accepted during the project period (16.4%) compared to the prior year (17.5%). Conversion from acceptance to transplant was higher under KAP (72.7% vs. 71.2%), though not significant. Waiting to accelerate placement after kidneys have been declined by multiple transplant programs locally and regionally is an intervention that may come too late to effectively increase utilization. Transplant rates of nationally shared and marginal kidneys remain a challenge, and future iterations of this project should be investigated.
86.
《Vaccine》2018,36(48):7430-7437
This report covers the topics of pandemics, epidemics and partnerships, including regulatory convergence initiatives, new technologies and novel vaccines, discussed by leading public and private sector stakeholders at the 18th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers’ Network (DCVMN). Contributions of Gavi and the vaccine industry from emerging countries to the growing global vaccine market, by improving the supply base from manufacturers in developing countries and contributing to 58% of doses, were highlighted. The Coalition for Epidemic Preparedness Innovations (CEPI), the International Vaccine Institute (IVI) and others reported on new strategies to ensure speedy progress in preclinical and clinical development of innovative vaccines for future MERS, Zika or other outbreak response. Priorities for vaccine stockpiling, to assure readiness during emergencies and to prevent outbreaks due to re-emerging diseases such as yellow fever, cholera and poliomyelitis, were outlined. The role of partnerships in improving global vaccine access, procurement and immunization coverage, and shared concerns were reviewed. The World Health Organization (WHO) and other international collaborating partners provided updates on the Product, Price and Procurement database, the prequalification of vaccines, the control of neglected tropical diseases, particularly the new rabies elimination initiative, and regulatory convergence proposals to accelerate vaccine registration in developing countries. Updates on supply chain innovations and novel vaccine platforms were presented. The discussions enabled members and partners to reflect on efficiency of research & development, supply chain tools and trends in packaging technologies improving delivery of existing vaccines, and allowing a deeper understanding of the current public-health objectives, industry financing, and global policies, required to ensure optimal investments, alignment and stability of vaccine supply in developing countries. 相似文献
87.
邹珺 《中国卫生政策研究》2011,4(6):39-44
产业的外贸竞争力决定其国际市场份额。对我国与GPA成员方以及印度的制剂产业外贸竞争力比较研究发现:我国制剂出口的国际市场占有率不足1%,贸易竞争优势指数为负值,显示性比较优势指数长期处于较低水平,制药产业外贸竞争力不仅与GPA成员相差悬殊,甚至明显落后于印度。因此,在我国制剂产业外贸竞争力取得长足进步之前,加入GPA难以改变目前我国单方面开放医药市场的现状,对我国制药产业很可能"弊大于利"。我国医药产业应借推行新版GMP和落实自主创新方略等政策的机会,加快企业"走出去"的步伐,争取在加入GPA之前成为真正的制药强国。 相似文献
88.
充分发挥公立医院党委的领导作用,履行全面从严治党主体责任,把基层党支部建设作为有力抓手,该文从风险防控角度分析医疗卫生行业设备及物资采购处岗位中的风险及关键点,探索构建风险明确、制度健全、宣教引导、监管有效的行风风险防控建设机制。 相似文献
89.
90.